PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study To Asses Mass Balance And Absolute Bioavailability Of 14C PF-06826647 In Healthy Male Participants
- Conditions
- Healthy
- Interventions
- Drug: 14C-PF-06826647-LR 600 mg PODrug: PF-06826647 600 mg PODrug: 14C-PF-06826647 100 ug IV
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT04591262
- Locations
- π³π±
PRA Health Sciences, Groningen, Netherlands
π³π±PRA Health Sciences Utrecht, Utrecht, Netherlands
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Drug: Sasanlimab Prefilled syringe
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 34
- Registration Number
- NCT04585815
- Locations
- πΊπΈ
City of Hope Investigational Drug Services (IDS), Duarte, California, United States
πΊπΈCity of Hope, Duarte, California, United States
πΊπΈUCSD Medical Center - Encinitas, Encinitas, California, United States
Clinical Study to Evaluate Pharmacokinetics and Safety of PF-06700841 After Single and Multiple Oral Doses as Modified Release Formulations
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2021-03-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT04580797
- Locations
- πΊπΈ
Quotient Sciences, Coral Gables, Florida, United States
πΊπΈQuotient Sciences-Miami, Miami, Florida, United States
A Study to Determine the Bioequivalence of Two Doses of Tafamidis
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2021-03-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 23
- Registration Number
- NCT04575116
- Locations
- πΊπΈ
New Haven Clinical Research Unit, New Haven, Connecticut, United States
Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1648
- Registration Number
- NCT04574362
- Locations
- π¨π³
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
π¨π³Anhui provincal Hospital, Hefei, Anhui, China
π¨π³The Second Hospital of Anhui Medical University, Hefei, Anhui, China
Randomized Trial in Adult Participants With Acute Migraines
- First Posted Date
- 2020-09-30
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1978
- Registration Number
- NCT04571060
- Locations
- πΊπΈ
Medical Affiliated Research Center, Huntsville, Alabama, United States
πΊπΈCoastal Clinical Research, LLC, An AMR Co., Mobile, Alabama, United States
πΊπΈMD First Research, Lancaster, South Carolina, United States
Abrocitinib Expanded Access Protocol in Adolescents and Adults With Moderate to Severe Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Pfizer
- Registration Number
- NCT04564755
- Locations
- πΊπΈ
Beach Allergy and Asthma Specialty Group, A Medical Corporation, Long Beach, California, United States
πΊπΈCahaba Dermatology and Skin Health Center, Birmingham, Alabama, United States
πΊπΈAntelope Valley Clinical Trials, Lancaster, California, United States
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- Conditions
- LiposarcomaAdenocarcinoma of LungProstate CancerBreast Neoplasms
- Interventions
- Combination Product: LetrozoleCombination Product: EnzalutamideCombination Product: Fulvestrant
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 337
- Registration Number
- NCT04557449
- Locations
- πΊπΈ
Ellison Institute, Los Angeles, California, United States
πΊπΈSmilow Cancer Hospital at Yale - New Haven, New Haven, Connecticut, United States
πΊπΈYale-New Haven Hospital-Yale Cancer Center, New Haven, Connecticut, United States
Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 80
- Registration Number
- NCT04556734
- Locations
- πΊπΈ
Investigate MD, Scottsdale, Arizona, United States
πΊπΈDermatology Trial Associates, Bryant, Arkansas, United States
πΊπΈCalifornia Dermatology & Clinical Research Institute, Encinitas, California, United States
Axitinib Therapy Management Study
- Conditions
- Renal Cell Carcinoma
- First Posted Date
- 2020-09-18
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Pfizer
- Registration Number
- NCT04555603
- Locations
- πΊπΈ
Pfizer Inc., New York, New York, United States